亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials

耶氏肺孢子虫 医学 荟萃分析 随机对照试验 肺炎 人类免疫缺陷病毒(HIV) 重症监护医学 肺孢子虫肺炎 艾滋病相关机会性感染 内科学 西达 病毒学 病毒性疾病
作者
Stefan Hatzl,Florian Posch,Laura Scholz,Christina Geiger,Lisa Kriegl,Philipp Kreuzer,Philipp Eller,Daniele Roberto Giacobbe,Matteo Bassetti,Martin Hoenigl,Robert Krause
出处
期刊:Clinical Microbiology and Infection [Elsevier BV]
卷期号:31 (5): 713-723 被引量:16
标识
DOI:10.1016/j.cmi.2024.12.024
摘要

BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in people living with HIV (PWH) who have low CD4 counts. Despite its side effects, trimethoprim-sulfamethoxazole (TMP-SMX) is currently considered the primary treatment for PCP. OBJECTIVES: The objectives of this study are to compare the efficacy (treatment failure and mortality) and tolerability (treatment change) of PCP treatment regimens with a frequentist network meta-analysis. DATA SOURCES: Data sources include Embase, Medline, and CENTRAL from inception to 3 February 2024. STUDY ELIGIBILITY CRITERIA: Study eligibility criteria include comparative randomized controlled trials (RCTs) of at least two PCP treatment regimens. PARTICIPANTS: Participants include PWH. INTERVENTIONS: Interventions include treatment regimens for PCP compared head-to-head. ASSESSMENT OF RISK OF BIAS: Assessment of risk of bias includes Cochrane Risk-of-bias tool for RCTs (Cochrane Risk-of-Bias 2). METHODS OF DATA SYNTHESIS: Title, abstract, and full-text screening, along with data extraction, were conducted by two independent reviewers. Data on PCP treatment failure, all-cause mortality, and discontinuation because of toxicity were pooled and ranked. RESULTS: Fourteen RCTs conducted between 1983 and 1996 included 1788 participants across 27 treatment arms. No regimen showed statistically significant superiority over TMP-SMX in direct comparison. In the network meta-analysis, clindamycin/primaquine was ranked the best (surface under the cumulative ranking curve, 0.8), followed by intravenous pentamidine (0.8) and TMP-SMX (0.8) regarding treatment failure. Regarding all-cause mortality, TMP-SMX was superior to atovaquone in direct comparison, but no treatment was superior in the full network analysis. Dapsone-TMP (0.7) and intravenous pentamidine (0.8) were ranked the highest for mortality reduction. For safety and tolerability, comparator drugs consistently outperformed TMP-SMX, with significant reductions in toxicity observed for dapsone-TMP, inhaled pentamidine, and atovaquone. Inhaled pentamidine (0.9) was the best tolerated, followed by trimetrexate (0.8) and atovaquone (0.8). CONCLUSIONS: We conclude that TMP-SMX should be reassessed as the standalone first-line therapy for PCP in PWH, given the better tolerability and comparable efficacy of other treatments. In places with access to alternative drugs for PCP treatment, our analysis suggests that alternative regimens may offer comparable effectiveness, providing flexibility to use alternative treatments when comorbidities necessitate it.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jf完成签到 ,获得积分10
刚刚
5秒前
cc发布了新的文献求助10
8秒前
科研通AI6.4的应助被祈愿采纳,获得10
8秒前
qiao完成签到,获得积分10
11秒前
Maestro_S的应助被cc采纳,获得10
12秒前
15秒前
jen完成签到 ,获得积分10
16秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
19秒前
斯文败类的应助被DRJ采纳,获得10
19秒前
华仔的应助被科研通管家采纳,获得10
19秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
19秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
19秒前
科目三的应助被科研通管家采纳,获得30
20秒前
Ava的应助被科研通管家采纳,获得10
20秒前
Isaac完成签到,获得积分10
20秒前
SGD完成签到,获得积分10
21秒前
corleeang完成签到 ,获得积分10
24秒前
丰富夏菡完成签到,获得积分10
26秒前
SGD发布了新的文献求助10
27秒前
null的应助被Ella采纳,获得10
31秒前
null的应助被Ella采纳,获得10
39秒前
40秒前
azhiyuan完成签到,获得积分10
42秒前
搜集达人的应助被DRJ采纳,获得10
45秒前
科研通AI6.4的应助被SUNny采纳,获得10
45秒前
九灶完成签到 ,获得积分10
48秒前
null的应助被Ella采纳,获得10
48秒前
56秒前
null的应助被Ella采纳,获得10
56秒前
小黑桃发布了新的文献求助10
1分钟前
1分钟前
沉默的元枫完成签到,获得积分10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
miu发布了新的文献求助10
1分钟前
1分钟前
务实寒烟完成签到,获得积分10
1分钟前
Lucas的应助被DRJ采纳,获得10
1分钟前
wanci的应助被刻苦香水采纳,获得10
1分钟前
Maestro_S的应助被window1000采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165939
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749898
捐赠科研通 7756692
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553385
邀请新用户注册赠送积分活动 2473623